CDH2 and cancer: During the naïve-to-primed transition, RAS activation mediates the epithelial-to-mesenchymal transition (EMT), characterized by the switch from epithelial cadherin (Ecad) to neural cadherin (Ncad)54; a process similar to cancer progression and tightly regulated by glycosylation55,56.